Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Equity Ratio (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Equity Ratio for 2 consecutive years, with 0.49 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 35.15% to 0.49 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.49 through Dec 2025, down 35.15% year-over-year, with the annual reading at 0.49 for FY2025, 35.15% down from the prior year.
  • Equity Ratio hit 0.49 in Q4 2025 for Prelude Therapeutics, down from 0.62 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.85 in Q1 2024 to a low of 0.49 in Q4 2025.